CN105030807B - Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug - Google Patents
Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug Download PDFInfo
- Publication number
- CN105030807B CN105030807B CN201510406371.4A CN201510406371A CN105030807B CN 105030807 B CN105030807 B CN 105030807B CN 201510406371 A CN201510406371 A CN 201510406371A CN 105030807 B CN105030807 B CN 105030807B
- Authority
- CN
- China
- Prior art keywords
- cerebral
- cerebral ischemia
- niacinamide ribose
- ribose
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to niacinamide ribose to prepare the application in treating Imaging in Patients with Cerebral Ischemia Disease drug.The present invention is by studying niacinamide ribose to blocking the influence of the brain infarction area for the cerebral ischemic model to be formed in intraluminal middle cerebral artery occlusion in rats coagulation; confirm that niacinamide ribose administration can obviously reduce brain infarction area; show that niacinamide ribose has significant Cerebral ischemia protection effect; cerebral injury caused by cerebral ischemia can be prevented has broad application prospects in terms of preparing cerebral ischemia and/or cerebral infarction related drugs.
Description
Technical field
The present invention relates to the new applications of compound, specifically, being related to niacinamide ribose is preparing treatment Imaging in Patients with Cerebral Ischemia Disease
Application in drug.
Background technology
Niacinamide ribose is a kind of ucleotides compound, and No. CAS is 1341-23-7, and structural formula is：
Having external report finds niacinamide ribose in obesity, hearing impairment, senile neurological retrogression pathological changes such as A Er
There is protective effect in the diseases such as Zi Haimo diseases (AD), Parkinson (PD), cognitive decline can be improved.Chinese patent literature
CN201510098227.9, publication date 2015.05.20 disclose niacinamide ribose and are preparing treatment non-alcoholic fatty liver
Application in scorching drug, passes through nonalcoholic fatty liver disease animal model, it was confirmed that niacinamide ribose can reduce animal
Liver lipids content, liver inflammation and the degree of hepatic fibrosis of model prompt niacinamide ribose to can be used for preparing the non-alcohol for the treatment of
The drug of property steatohepatitis.
However, there is no the document report of protective effect of the niacinamide ribose to cerebral ischemia at present.
Invention content
The purpose of the present invention is being directed to deficiency in the prior art, the new application of niacinamide ribose is provided.
In the first aspect of the present invention, niacinamide ribose answering in the drug for preparing prevention cerebral ischemia is provided
With.
As a kind of specific implementation mode of the present invention, the prevention cerebral ischemia refers to reducing brain infarction area.
In the second aspect of the present invention, the application of niacinamide ribose in medicine preparation is provided, the drug is used for
Reduce the brain infarction area of cerebral ischemia.
In the third aspect of the present invention, application of the niacinamide ribose in the drug for preparing prevention cerebral infarction is provided.
Herein, the niacinamide ribose structural formula is：
Herein, " cerebral ischemia " refers to the cranium including TIA, cerebral infarction and Moyamoya Disease (but being not limited only to this)
Interior vascular lesion, caused main pathological change are that cerebral ischemia is damaged.Generally speaking, " cerebral ischemia " may be by following
Reason causes：1. the inside and outside arteriarctia of cranium or occlusion；2. cerebral embolism；3. Hemodynamic Factors；4. hematologic agent
Deng.The main reason for causing cerebral arterial stenosis or occlusion is atherosclerosis.The main reason for causing cerebral embolism include
Atherosclerosis, and because with rheumatic valvular heart disease, subacute bacterial endocarditis, congenital heart disease, artificial
Embolism caused by the embolus of the formation such as valve and openheart surgery enters intracerebral with blood flow.Hemodynamic Factors include of short duration low
The cerebral ischemia that blood pressure causes, such as myocardial infarction, severe arrhythmia, shock, carotid sinus hypersensitivity, orthostatic hypotension, lock
Artery steal syndrome etc. under bone.Hematologic agent includes after oral contraceptive, gestation, puerpera, operation and thrombocythemia
High blood coagulation state caused by disease, stickiness caused by polycythemia, sickle cell anemia, macroglobulinemia increase institute
Caused cerebral ischemia.
The invention has the advantages that：The present invention to be formed by studying niacinamide ribose to blocking in intraluminal middle cerebral artery occlusion in rats coagulation
Cerebral ischemic model brain infarction area influence, it was demonstrated that niacinamide ribose administration can obviously reduce brain infarction area, show cigarette
Amide ribose has significant Cerebral ischemia protection effect, can prevent cerebral injury caused by cerebral ischemia, prepare cerebral ischemia
And/or it has broad application prospects in terms of cerebral infarction related drugs.The present invention provides new medicament research and development side for cerebral ischemia
To.
Description of the drawings
The representative picture of Fig. 1 TTC dyeing.
Specific implementation mode
It elaborates below in conjunction with the accompanying drawings to specific implementation mode provided by the invention.
Embodiment 1
One, method
It is made with rat (Sprague-Dawley rats, weight 250g or so, Shanghai Slac Experimental Animal Co., Ltd.)
Standby permanent cerebral ischemia damage model.Process is as follows：By rat anesthesia, skull is opened, directly by arteria cerebri media under visually
Coagulation causes left side arteria cerebri media to block.Rats by intraperitoneal injection niacinamide ribose is given after 30 minutes, and (30mg/kg is purchased from
The bio tech ltd Hai Hanxiang).The physiological saline that control group gives 0.9% is injected intraperitoneally.Skull is resetted, skin is sutured
Skin successfully prepares permanent cerebral ischemia model caused by intraluminal middle cerebral artery occlusion in rats blocks.24 hours after arteria cerebri media blocking,
Give detection brain infarction area.Cerebral infarction volume detection is using 2,3,5- triphenyltetrazolium chlorides (being purchased from Amersco companies)
Decoration method, i.e. TTC decoration methods.
Two, result
The representative picture of TTC dyeing is shown in that Fig. 1, cerebral infarction volume statistical result are shown in Table 1.The result shows that：Niacinamide ribose is bright
Aobvious brain infarction area (the P for reducing rat<0.001), show that it can be to anti-cerebral ischemia damnification.
1 saline control group of table and niacinamide ribose to treat group Brain stem injury (%)
Note：***P<0.001vs control groups, N=10.Number in table is the percentage that cerebral infarction accounts for full brain range.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, under the premise of not departing from the method for the present invention, can also make several improvement and supplement, these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (3)
1. the application of niacinamide ribose in medicine preparation, which is characterized in that the drug is used to reduce the cerebral infarction of cerebral ischemia
Unleavened dough accumulates.
2. application of the niacinamide ribose in the drug for preparing prevention cerebral infarction.
3. application according to claim 1 or 2, which is characterized in that the niacinamide ribose structural formula is：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406371.4A CN105030807B (en) | 2015-07-13 | 2015-07-13 | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406371.4A CN105030807B (en) | 2015-07-13 | 2015-07-13 | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105030807A CN105030807A (en) | 2015-11-11 |
| CN105030807B true CN105030807B (en) | 2018-11-06 |
Family
ID=54438174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406371.4A Active CN105030807B (en) | 2015-07-13 | 2015-07-13 | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030807B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412247A (en) * | 2016-05-23 | 2017-12-01 | 上海风劲生物医药科技有限公司 | Application of the nicotinamide mononucleotide in prevention or treatment cerebral hemorrhage medicine is prepared |
| CN107536844A (en) * | 2017-06-30 | 2018-01-05 | 上海风劲生物医药科技有限公司 | Application of the nicotinamide mononucleotide in the medicine for preparing prevention or treatment rtPA vascular complications |
| US20230119002A1 (en) * | 2020-03-09 | 2023-04-20 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601679A (en) * | 2009-03-17 | 2009-12-16 | 中国人民解放军第二军医大学 | A kind of application of nicotinamide mononucleotide. |
| CN104367587A (en) * | 2013-12-06 | 2015-02-25 | 中国人民解放军第二军医大学 | Application of nicotinamide mononucleotide in preparation of medicines for promotion of nerve regeneration after cerebral ischemia |
-
2015
- 2015-07-13 CN CN201510406371.4A patent/CN105030807B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601679A (en) * | 2009-03-17 | 2009-12-16 | 中国人民解放军第二军医大学 | A kind of application of nicotinamide mononucleotide. |
| CN104367587A (en) * | 2013-12-06 | 2015-02-25 | 中国人民解放军第二军医大学 | Application of nicotinamide mononucleotide in preparation of medicines for promotion of nerve regeneration after cerebral ischemia |
Non-Patent Citations (1)
| Title |
|---|
| 脂肪因子visfatin的调节与功能多样性;油红捷等;《生物化学与生物物理进展》;20081231;第35卷(第12期);1351-1357 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105030807A (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fang et al. | Rapamycin alleviates cisplatin-induced ototoxicity in vivo | |
| CN105030807B (en) | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug | |
| CA2747395C (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| CA2747396C (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| WO2010004435A3 (en) | Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders | |
| MX2010001711A (en) | Extended release compositions comprising mycophenolate sodium and processes thereof. | |
| WO2015152416A1 (en) | Ocular hypotensive agent | |
| CN110327374A (en) | A kind of pharmaceutical composition for being used to prevent and/or treat convulsions prepared with maggot | |
| CA2885106C (en) | Use of 3-n-butyl isoindoline ketone in preparation of drugs for preventing and treating cerebral infarction | |
| WO2009039356A1 (en) | Treatment methods with brimonidine | |
| CN104997771B (en) | Compound P7C3 A20 are preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease medicine | |
| CN107865875A (en) | A kind of pharmaceutical composition containing Aescinate A | |
| US11717013B1 (en) | Micronutrient combination to reduce blood pressure | |
| CN108042553A (en) | A kind of pharmaceutical composition for being used to treat cerebral arterial thrombosis | |
| JP2004331502A (en) | Optical nerve cell protecting agent | |
| RU2481124C1 (en) | Pharmaceutical combination of atorvastatin and nicergolin for preventing or treating cerebrovascular disease | |
| JP2000229854A (en) | Intracerebral administering agent for treatment and prophylaxis of ischemic neurocyte apoptosis, intracerebral administering agent for treatment and prophylaxis of vascular dementia and administering agent in intracerebral surgery | |
| CN104623635B (en) | Pharmaceutical composition for preventing and treating cerebral ischemia | |
| CA2817505C (en) | Pharmaceutical formulation having neuroprotective activity | |
| Yasa et al. | Utility of mild hypothermia during carotid artery surgery in patients with unilateral stenosis and contralateral total occlusion/Kontrlateral total oklüzyonlu karotid arter stenozu olan olgularda hafif hipotermi ile karotid arter cerrahisi | |
| KR101768809B1 (en) | Pharmaceutical Composition Comprising Dexamethasone and Glibenclamide for Prevention or Treatment of Stroke | |
| JP2024503490A (en) | Application of compositions containing cilostazol to cerebrovascular diseases | |
| JP6609322B2 (en) | 4-Phenylbutyric acid derivative | |
| JP2024505853A (en) | Application of a composition containing riluzole and ronin to the preparation of a cerebrovascular therapeutic drug | |
| WO2021048871A1 (en) | Synergistic bioactive compositions for treating neurological disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |